Vaccine News and Research

Latest Vaccine News and Research

Bellicum Pharmaceuticals announces $4.5 million in Series A and Convertible Note funding

Bellicum Pharmaceuticals, Inc. today announced $4.5 million in Series A and Convertible Note funding. The new funds will be used to complete the company's ongoing Phase I/IIa trial of BP-GMAX-CD1 in patients with advanced, androgen independent prostate cancer, and to prepare for Phase IIb trials. The company anticipates reporting initial results of the Phase I/IIa trial in mid 2010.

27 Oct 2009

China places third purchase order for H1N1 vaccine with Sinovac Biotech

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has received its third purchase order for its H1N1 vaccine, PANFLU.1, from China's Ministry of Industry and Information Technology for the national stockpiling plan.

27 Oct 2009

Boston Medical Center deploys Fusionfx Immunization Management portal to manage H1N1 vaccination

Acknowledging the critical role of Centers for Disease Control and Prevention (CDC) guidelines in ensuring the safety and efficacy of H1N1 vaccinations, Carefx Corporation, a leading provider of interoperable workflow solutions to advance the quality and safety of patient care, today announced that Boston Medical Center (BMC) has deployed the Fusionfx Immunization Management portal designed to enter and track H1N1 vaccination administration history and support broad, community-wide immunization administration tracking.

27 Oct 2009

NCMLS organises immunology congress at Nijmegen

How do cells in our immune system recognise dangerous invaders and hazardous cells, such as cancer cells? Answers to this and similar questions are evolving rapidly. A large contributor worldwide to the field of immunology is the NCMLS, Nijmegen Centre for Molecular Life Sciences of the Radboud University Nijmegen Medical Centre. The NCMLS is organising an important scientific congress on this very topic, for which the absolute world top immunology experts are coming to Nijmegen.

27 Oct 2009

Vaccination rates need improvement; racial and ethnic disparities in vaccination coverage

More teenagers are being vaccinated against human papillomavirus (HPV), meningococcal meningitis and pertussis (whooping cough), though the rates are still too low, according to recently released government data and a panel of experts convened by the National Foundation for Infectious Diseases (NFID).

27 Oct 2009

Hutchinson Center receives USAID grant to build a cancer clinic and medical-training facility in Africa

Building on the strengths of two institutions separated by nearly 9,000 miles over two continents - both renowned in their work in the fight against cancer - the United States Agency for International Development has awarded a $500,000 grant to Fred Hutchinson Cancer Research Center to aid in the construction of the first American cancer clinic and medical-training facility in Africa.

27 Oct 2009

Genomics can provide insights in understanding emerging infectious disease

This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease.

27 Oct 2009

Issuance of patents for Idera Pharmaceuticals' TLR-targeted compounds announced

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance of patents covering its novel Toll-like Receptor (TLR) - targeted compounds. The Company’s TLR-targeted compounds are based on synthetic DNA and RNA, which it refers to as immune modulatory oligonucleotides, or IMO®.

27 Oct 2009

New Pandemic Influenza Stress Vaccine course for health-care workers

Experts know that a pandemic can increase stress-related absenteeism among health-care workers. To help prevent this, a team of Mount Sinai Hospital psychiatrists and nurses have developed The Pandemic Influenza Stress Vaccine, a computerized course for health-care workers worldwide to build their resilience during a pandemic.

27 Oct 2009

Fred Hutchinson Cancer Research Center receives a $500,000 grant to construct cancer clinic in Africa

27 Oct 2009

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.

27 Oct 2009

President Obama declares H1N1 national emergency

President Barack Obama declared the H1N1 (swine) flu outbreak a national emergency, the Wall Street Journal reports. "The declaration, which Mr. Obama signed Friday, authorizes the administration to waive or modify certain federal requirements involving Medicare, Medicaid and health-privacy rules to speed treatment," the newspaper writes (McKay/Simpson/Whalen, 10/26).

26 Oct 2009

Swine flu 'emergency' declaration could mean expedited care

President Barack Obama declared a state of emergency as the number of swine flu cases soars and vaccine production doesn't keep up with demand.

26 Oct 2009

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.

26 Oct 2009

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.

26 Oct 2009

AMERIGROUP issues new guidance for third quarter 2009

AMERIGROUP Corporation announced today that it expects to report earnings for the third quarter of 2009 in the range of $0.42 to $0.44 per diluted share. The new guidance for the third quarter primarily reflects elevated medical costs associated with the onset of a severe flu season due to the H1N1 virus.

26 Oct 2009

Rega Institute and CD3 to receive funds for new medication research for dengue treatment

The Laboratory for Virology and Experimental Chemotherapy (Rega Institute) and the "Centre for Drug Design and Discovery" (CD3) at K.U.Leuven will receive a total of 2.8 million euro from the British Wellcome Trust. - They will apply these funds to the search for possible new medication for the treatment of infections related to the 'dengue fever virus'.

26 Oct 2009

H1N1 swine flu vaccine consent forms for Maryland Department of Health processed by Quality Associates

Quality Associates, Inc. (QAI) www.qualityassociatesinc.com, an established provider of services and solutions for large-scale document management, imaging, and archiving, announced it is processing H1N1 swine flu vaccine consent forms on behalf of the Maryland Department of Health and Mental Hygiene.

26 Oct 2009

Wellcome Trust's 91M fund aims at developing new drugs related to the dengue fever virus

The Wellcome Trust spends over 600 million pounds each year to support its mission to foster and promote research with the aim to improving human and animal health. This funding supports basic research as well as technology transfer, the transfer of academic knowledge and technology to the corporate environment.

26 Oct 2009

Doctoral candidate sheds new light on the biology of Leishmania parasites

Professor Albert Descoteaux's team at Centre INRS - Institut Armand-Frappier has gained a better understanding of how the Leishmania donovani parasite manages to outsmart the human immune system and proliferate with impunity, causing visceral leishmaniasis, a chronic infection that is potentially fatal if left untreated.

24 Oct 2009

Vaccine News and Research

Latest Vaccine News and Research

Bellicum Pharmaceuticals announces $4.5 million in Series A and Convertible Note funding

China places third purchase order for H1N1 vaccine with Sinovac Biotech

Boston Medical Center deploys Fusionfx Immunization Management portal to manage H1N1 vaccination

NCMLS organises immunology congress at Nijmegen

Vaccination rates need improvement; racial and ethnic disparities in vaccination coverage

Hutchinson Center receives USAID grant to build a cancer clinic and medical-training facility in Africa

Genomics can provide insights in understanding emerging infectious disease

Issuance of patents for Idera Pharmaceuticals' TLR-targeted compounds announced

New Pandemic Influenza Stress Vaccine course for health-care workers

Fred Hutchinson Cancer Research Center receives a $500,000 grant to construct cancer clinic in Africa

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

President Obama declares H1N1 national emergency

Swine flu 'emergency' declaration could mean expedited care

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

AMERIGROUP issues new guidance for third quarter 2009

Rega Institute and CD3 to receive funds for new medication research for dengue treatment

H1N1 swine flu vaccine consent forms for Maryland Department of Health processed by Quality Associates

Wellcome Trust's 91M fund aims at developing new drugs related to the dengue fever virus

Doctoral candidate sheds new light on the biology of Leishmania parasites

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vaccine News and Research

Latest Vaccine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in